While loop diuretics and thiazides dominate clinical diuretic practice, four additional classes address specific physiological targets and clinical problems that the major diuretics cannot. Mineralocorticoid receptor (MR) antagonists and epithelial sodium channel (ENaC) blockers both act in the collecting duct to block aldosterone-driven sodium retention while preserving potassium, making them essential in heart failure, cirrhosis, resistant hypertension, and hyperaldosteronism. Carbonic anhydrase (CA) inhibitors exploit the proximal tubule's bicarbonate reabsorption mechanism to create intentional metabolic acidosis, with utility in altitude sickness, glaucoma, and alkalosis management. Osmotic diuretics act by a distinct principle, filtering freely and drawing water osmotically, with an irreplaceable role in cerebral edema and acute angle-closure glaucoma. Vasopressin antagonists selectively block aquaporin-2 (AQP2) insertion in the collecting duct to produce electrolyte-free water excretion (aquaresis) without natriuresis, a unique pharmacological action suited to hyponatremia management.
Spironolactone is a steroidal mineralocorticoid receptor (MR) antagonist that competitively blocks aldosterone binding at the MR in the principal cells of the collecting duct (CD), reducing the transcription of genes encoding the epithelial sodium channel (ENaC) and the Na/K-ATPase on the basolateral membrane. By preventing aldosterone-driven upregulation of ENaC, spironolactone reduces luminal sodium entry and the associated potassium secretion via the renal outer medullary potassium channel (ROMK), producing natriuresis with potassium retention. Spironolactone does not act directly as a tubular transport blocker; its effects are slow in onset (24–72 hours) because they depend on transcriptional downregulation rather than direct transporter inhibition.1
Spironolactone's lack of MR selectivity generates clinically significant endocrine adverse effects. Its active metabolite canrenone, along with the parent compound, binds to androgen and progesterone receptors, producing gynecomastia, breast tenderness, and menstrual irregularities at rates that are dose-dependent and well-established in clinical trials. These effects limit tolerability, particularly in men requiring long-term therapy for heart failure or cirrhosis. Hyperkalemia is the most serious adverse effect and is the primary safety concern limiting use in chronic kidney disease (CKD) and in patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), where dual renin-angiotensin-aldosterone system (RAAS) blockade markedly amplifies potassium retention.1,2
Eplerenone is a more selective steroidal MR antagonist with approximately 40-fold lower affinity for androgen and progesterone receptors than spironolactone, substantially reducing the incidence of gynecomastia and menstrual irregularities. It is metabolized primarily by cytochrome P450 3A4 (CYP3A4), making it subject to significant drug interactions with strong CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, ritonavir-boosted antiretrovirals) and inducers (rifampin, carbamazepine). The EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trial demonstrated that eplerenone reduced cardiovascular death or heart failure hospitalization in patients with mild heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization, establishing MR antagonism as a standard pillar of heart failure with reduced ejection fraction therapy.3
Finerenone is a nonsteroidal MR antagonist with a distinct chemical scaffold that provides greater MR selectivity than either spironolactone or eplerenone and a different tissue distribution profile, with higher relative cardiac expression binding and lower renal expression binding than steroidal agents. This translates clinically into a reduced incidence of hyperkalemia compared with spironolactone or eplerenone at equivalent MR-blocking doses. The FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) trial demonstrated that finerenone reduced the composite of kidney failure, sustained eGFR decline, and renal death in patients with type 2 diabetes and CKD, and the FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease) trial demonstrated cardiovascular benefit in the same population, establishing finerenone as a disease-modifying agent in diabetic CKD.45
Risk is additive across multiple factors: CKD (reduced urinary potassium excretion), concurrent ACE inhibitor or ARB use, diabetes (hyporeninemic hypoaldosteronism is common), baseline potassium above 4.5 mEq/L, and high-potassium diet. Serum potassium and eGFR must be checked within 1–2 weeks of initiation and after any dose change. MR antagonists are generally contraindicated when eGFR falls below 30 mL/min/1.73 m² or baseline potassium exceeds 5.0 mEq/L.
Amiloride and triamterene block the epithelial sodium channel (ENaC) directly at the luminal surface of the collecting duct (CD) and connecting tubule, reducing sodium entry into principal cells independently of aldosterone. Unlike mineralocorticoid receptor (MR) antagonists, their effect is immediate and does not require transcriptional downregulation. Because ENaC-mediated sodium absorption creates the lumen-negative potential that drives potassium secretion via the renal outer medullary potassium channel (ROMK), ENaC blockade reduces both sodium absorption and potassium secretion simultaneously, producing mild natriuresis with potassium retention. The potassium-sparing effect is consistent regardless of aldosterone status, distinguishing this class from MR antagonists, which are most effective when aldosterone is elevated.1
Amiloride has a favorable pharmacokinetic profile with reliable oral bioavailability and predominantly renal elimination. Its hyperkalemia risk is directly proportional to the degree of ENaC blockade and to the patient's baseline potassium-handling capacity; the combination with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or MR antagonists increases hyperkalemia risk substantially and requires close monitoring. Amiloride has a specific clinical role in patients requiring a diuretic while on lithium for mood stabilization: it does not promote the proximal sodium-lithium cotransport upregulation that characterizes loop and thiazide diuretics, making it the preferred diuretic in this setting.6 Amiloride is also first-line treatment for lithium-induced nephrogenic diabetes insipidus (NDI), where it reduces lithium entry into collecting duct cells by blocking ENaC-mediated lithium uptake, attenuating aquaporin-2 (AQP2) downregulation and improving urinary concentrating ability.
Triamterene has a similar mechanism to amiloride but is a prodrug requiring hepatic activation to its active hydroxytriamterene metabolite. This hepatic dependency reduces its effectiveness in patients with significant hepatic dysfunction or end-stage liver disease, making amiloride the preferred ENaC blocker in cirrhosis. Triamterene is renally eliminated and accumulates in chronic kidney disease (CKD), amplifying hyperkalemia risk. Both amiloride and triamterene are more commonly used as combination components with thiazide diuretics (Dyazide, Maxzide, Moduretic) than as standalone agents, where their potassium-sparing effect offsets thiazide-induced kaliuresis.
1. Lithium-treated patients needing a diuretic: amiloride does not upregulate proximal lithium reabsorption and does not raise lithium levels. 2. Lithium-induced nephrogenic diabetes insipidus: amiloride blocks lithium entry into collecting duct cells via ENaC, reducing AQP2 (aquaporin-2) downregulation and improving urinary concentration. These are high-yield clinical distinctions not shared by loop diuretics or thiazides.
Acetazolamide inhibits carbonic anhydrase (CA), the enzyme that catalyzes the reversible hydration of carbon dioxide to carbonic acid (CO₂ + H₂O ⇌ H₂CO₃ ⇌ H⁷ + HCO₃⁻). In the proximal convoluted tubule (PCT), luminal carbonic anhydrase (CA IV) is essential for the dehydration of carbonic acid that allows bicarbonate to be reabsorbed. When acetazolamide inhibits both luminal CA IV and cytoplasmic CA II, the coupled sodium-hydrogen exchanger isoform 3 (NHE3)-mediated reabsorption of sodium and bicarbonate is impaired. The consequence is urinary wasting of sodium bicarbonate (NaHCO₃) and a predictable, dose-dependent metabolic acidosis. This intentional alkaline urine and systemic acidosis is the therapeutic basis for all of acetazolamide's clinical applications.7
At high altitude, hypoxic hyperventilation lowers PaCO₂ and raises arterial pH, producing a respiratory alkalosis that blunts the hypoxic ventilatory response and worsens altitude sickness symptoms including headache, nausea, and disturbed sleep. Acetazolamide-induced metabolic acidosis counteracts this respiratory alkalosis, restoring the acid stimulus to peripheral chemoreceptors and maintaining ventilatory drive at altitude. For altitude sickness prophylaxis, acetazolamide is started 1–2 days before ascent at 125–250 mg twice daily. It is sulfonamide-derived, so patients with sulfonamide allergy require alternative prophylaxis (dexamethasone).7
In open-angle glaucoma, acetazolamide reduces aqueous humor production by inhibiting ciliary body CA, lowering intraocular pressure independent of its diuretic effect. It is used when topical agents fail to achieve adequate intraocular pressure control. In acute angle-closure glaucoma, IV acetazolamide is used as an emergency temporizing measure to reduce intraocular pressure while definitive surgical intervention is arranged. In the management of metabolic alkalosis complicating diuretic therapy in volume-overloaded patients (who cannot receive the saline that would normally correct contraction alkalosis), acetazolamide forces bicarbonaturia and restores near-normal serum bicarbonate without sodium loading, making it a clinically important tool in decompensated heart failure or pulmonary hypertension with concurrent alkalosis.78
Thiazide and loop diuretics cause metabolic alkalosis through contraction, hypokalemia, and hyperaldosteronism. Correcting this normally requires saline and potassium repletion. In patients who are volume-overloaded (heart failure, pulmonary hypertension) and cannot receive saline, acetazolamide 250–500 mg forces bicarbonaturia and lowers serum bicarbonate without sodium loading. This is one of the most underused applications of acetazolamide in clinical nephrology and critical care.
Mannitol is a six-carbon sugar alcohol that is freely filtered at the glomerulus and neither reabsorbed nor secreted by the renal tubule. Its presence in the tubular lumen exerts an osmotic force that holds water in the lumen and opposes tubular water reabsorption, increasing urine output in proportion to its luminal concentration. In the proximal convoluted tubule (PCT), where the majority of water reabsorption is obligatorily coupled to solute transport, mannitol's osmotic effect limits water reclamation and increases tubular flow rate. The increased tubular flow also dilutes the concentration of other solutes, reducing the driving force for their reabsorption and producing a modest natriuresis and electrolyte loss alongside the primary diuresis.9
The primary clinical application of mannitol is reduction of elevated intracranial pressure (ICP) in the acute management of cerebral edema from traumatic brain injury, ischemic stroke with hemispheric swelling, hypertensive encephalopathy, or mass lesions. Mannitol reduces ICP through two mechanisms: the rapid osmotic gradient it creates draws water from brain parenchyma into plasma, reducing brain water content within 15–30 minutes; and by reducing blood viscosity, it transiently improves cerebral blood flow, allowing compensatory autoregulatory vasoconstriction that further reduces cerebral blood volume. Standard dosing is 0.25–1 g/kg IV over 20–30 minutes, with repeated dosing titrated to serum osmolality (target 310–320 mOsm/kg). Mannitol is also used in acute angle-closure glaucoma (when IV acetazolamide and topical agents are insufficient) and in rhabdomyolysis to maintain tubular flow and prevent cast formation and tubular obstruction by myoglobin.9
The contraindications to mannitol are as clinically important as its indications. In heart failure, mannitol's initial intravascular volume expansion (as it draws water from tissues into plasma) can precipitate acute decompensation and pulmonary edema before the diuretic effect takes hold. In anuric patients, mannitol cannot be excreted and accumulates in plasma, expanding intravascular volume and causing hypertonicity, hyponatremia, and pulmonary edema without any therapeutic benefit. In hypervolemic states from any cause, mannitol is contraindicated for the same reason. Hyperosmolality (serum osmolality above 320 mOsm/kg) is a relative contraindication; continued dosing above this threshold increases the risk of renal tubular toxicity from hyperosmolar injury and paradoxically worsening cerebral edema as the osmotic gradient dissipates.9
Vasopressin (antidiuretic hormone, ADH) acts on vasopressin type 2 (V2) receptors in the principal cells of the collecting duct (CD) to stimulate cyclic AMP (cAMP) production, which triggers the insertion of aquaporin-2 (AQP2) water channels into the apical membrane, allowing water to move from the tubular lumen into the hypertonic medullary interstitium and concentrate urine. Vasopressin antagonists (vaptans) block this process at the V2 receptor, preventing AQP2 insertion and allowing the excretion of electrolyte-free water — a process termed aquaresis, which is mechanistically distinct from natriuresis. Because aquaresis removes water without sodium, vaptans raise serum sodium without causing sodium depletion, making them uniquely suited to the treatment of hypervolemic and euvolemic hyponatremia, particularly the syndrome of inappropriate antidiuretic hormone secretion (SIADH).10
Tolvaptan is a selective oral V2 receptor antagonist approved for hypervolemic and euvolemic hyponatremia (serum sodium below 125 mEq/L, or below 130 mEq/L with symptoms) in hospitalized patients, and separately for the slowing of kidney cyst growth in autosomal dominant polycystic kidney disease (ADPKD). The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes trial (TEMPO 3:4) demonstrated that tolvaptan slowed the increase in total kidney volume and reduced the rate of eGFR decline in patients with rapidly progressive ADPKD, establishing it as the first disease-modifying pharmacological therapy for this condition.11 Tolvaptan carries a boxed warning for hepatotoxicity, with cases of serious and potentially fatal liver injury documented in the ADPKD indication, where it is used for years rather than days. For this reason, tolvaptan use in ADPKD is restricted to patients with rapidly progressing disease (ADPKD risk class 1C, 1D, or 1E based on the Mayo classification), and liver function tests must be monitored before and during treatment.10
Conivaptan is a non-selective vasopressin antagonist that blocks both V1a receptors (on vascular smooth muscle, where vasopressin promotes vasoconstriction) and V2 receptors, and is available only as an IV formulation for use in hospitalized patients with euvolemic or hypervolemic hyponatremia. The additional V1a blockade produces some vasodilation, which limits its use in hypotensive patients. Conivaptan is a potent inhibitor of cytochrome P450 3A4 (CYP3A4) and has a significant drug interaction burden, which contributed to its restriction to the inpatient IV setting. For both tolvaptan and conivaptan, the rate of sodium correction is the dominant safety concern: too-rapid correction of hyponatremia (greater than 8–10 mEq/L in 24 hours or 18 mEq/L in 48 hours) risks osmotic demyelination syndrome (ODS), a devastating neurological injury affecting the pons and extrapontine structures that presents with dysarthria, dysphagia, spastic paraparesis, and in severe cases locked-in syndrome. Patients must be monitored continuously, and vaptans should be initiated only in monitored inpatient settings.10
Loop diuretics and thiazides produce natriuresis (water loss with sodium loss) and can worsen hyponatremia by depleting sodium faster than water in some settings. Vaptans produce aquaresis (pure water loss without sodium loss) and raise serum sodium without depleting total body sodium. This makes vaptans appropriate for hyponatremia where total body sodium is normal or elevated (SIADH, heart failure, cirrhosis), but they should not be used when hyponatremia is caused by total body sodium depletion (hypovolemic hyponatremia), where the correct treatment is saline replacement.
Sequential nephron blockade is the strategy of combining diuretics that act at different tubular sites to prevent compensatory sodium reabsorption from occurring downstream of the site blocked by the primary diuretic. With chronic loop diuretic use, the distal convoluted tubule (DCT) and collecting duct (CD) principal cells hypertrophy and upregulate the Na-Cl cotransporter (NCC), epithelial sodium channel (ENaC), and Na/K-ATPase in response to chronically elevated sodium and fluid delivery. This structural adaptation allows the DCT and CD to reabsorb a significantly greater fraction of the sodium that the loop diuretic delivers to them, partially negating the loop diuretic's natriuretic effect over time. Adding a diuretic that blocks NCC or ENaC simultaneously prevents this compensatory reabsorption and restores an effective natriuretic response.12
The most clinically used sequential blockade combination is a loop diuretic plus metolazone, a thiazide-like agent that blocks NCC and retains efficacy even when glomerular filtration rate (GFR) falls below 30 mL/min/1.73 m². Metolazone is dosed 30–60 minutes before the loop diuretic dose to allow NCC blockade to be established before the loop diuretic-driven sodium arrives at the DCT. The natriuretic effect can be dramatic, and the risk of severe hypokalemia, volume depletion, and acute kidney injury (AKI) is real; electrolytes and renal function must be monitored within 24–48 hours of initiation. Hydrochlorothiazide (HCTZ) can be substituted for metolazone but loses efficacy at GFR below 30 mL/min/1.73 m², limiting its utility in the patients most likely to require aggressive combination diuresis.1
Loop diuretics combined with mineralocorticoid receptor (MR) antagonists represent a physiologically complementary pairing: the loop diuretic maximizes natriuresis through Na-K-2Cl cotransporter isoform 2 (NKCC2) blockade, while the MR antagonist blocks aldosterone-driven compensatory ENaC upregulation in the CD, preventing the secondary hyperaldosteronism triggered by volume depletion from worsening potassium loss. This combination is standard of care in heart failure with reduced ejection fraction (HFrEF) and in cirrhotic ascites, where secondary hyperaldosteronism is a dominant driver of sodium retention. ENaC blockers (amiloride, triamterene) can serve a similar potassium-protective role when added to loop or thiazide diuretics, though MR antagonists are preferred when the clinical indication extends to aldosterone-mediated fibrosis and cardiovascular remodeling.
Acetazolamide represents a third combination strategy, particularly useful in heart failure or pulmonary hypertension patients who have developed metabolic alkalosis from loop or thiazide therapy. Metabolic alkalosis reduces the natriuretic response to loop diuretics by increasing proximal bicarbonate reabsorption via angiotensin II (Ang II)-driven sodium-hydrogen exchanger isoform 3 (NHE3) upregulation, which indirectly enhances sodium and chloride retention. A short course of acetazolamide corrects the alkalosis, restores the tubular pH milieu that favors loop diuretic efficacy, and produces additional natriuresis through bicarbonaturia. The ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial demonstrated that acetazolamide added to IV loop diuretics increased the rate of successful decongestion at 3 days compared with placebo in hospitalized decompensated heart failure patients, providing trial evidence for this combination strategy, and the DOSE (Diuretic Optimization Strategies Evaluation) trial established the superiority of high-dose IV loop diuretics in this setting.812
First: IV loop diuretic at adequate dose (2.5× oral daily dose per DOSE trial). Second: increase frequency. Third: add metolazone 30–60 min before loop dose (sequential NCC + NKCC2 blockade). Fourth: add acetazolamide if metabolic alkalosis is present (restores loop diuretic responsiveness and provides additional bicarbonaturia). Fifth: MR antagonist if not already on board (blocks CD compensatory reabsorption and secondary hyperaldosteronism). Monitor electrolytes and renal function within 24–48 hours of each addition.
Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–1975.
doi:10.1056/NEJMra1703100Hoorn EJ, Ellison DH. Diuretic resistance. Am J Kidney Dis. 2017;69(1):136–142.
doi:10.1053/j.ajkd.2016.08.027Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
doi:10.1056/NEJMoa1009492Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
doi:10.1056/NEJMoa2025845Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263.
doi:10.1056/NEJMoa2110956Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med. 1985;312(7):408–414.
doi:10.1056/NEJM198502143120705Swenson ER. Carbonic anhydrase inhibitors and high altitude illnesses. Subcell Biochem. 2014;75:361–386.
doi:10.1007/978-94-007-7359-2_18Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387(13):1185–1195.
doi:10.1056/NEJMoa2203094Sorani MD, Manley GT. Dose-response relationship of mannitol and intracranial pressure: a metaanalysis. J Neurosurg. 2008;108(1):80–87.
doi:10.3171/JNS/2008/108/01/0080Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42.
doi:10.1016/j.amjmed.2013.07.006Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418.
doi:10.1056/NEJMoa1205511Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.
doi:10.1056/NEJMoa1005419